Benedetta Conte

2.2k total citations · 1 hit paper
41 papers, 574 citations indexed

About

Benedetta Conte is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Benedetta Conte has authored 41 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 23 papers in Cancer Research and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Benedetta Conte's work include Breast Cancer Treatment Studies (22 papers), Advanced Breast Cancer Therapies (16 papers) and HER2/EGFR in Cancer Research (14 papers). Benedetta Conte is often cited by papers focused on Breast Cancer Treatment Studies (22 papers), Advanced Breast Cancer Therapies (16 papers) and HER2/EGFR in Cancer Research (14 papers). Benedetta Conte collaborates with scholars based in Italy, Spain and United States. Benedetta Conte's co-authors include Lucia Del Mastro, Francesca Poggio, Matteo Lambertini, Francesco Schettini, Aleix Prat, Olga Martínez‐Sáez, Tomás Pascual, María Vidal, Fara Brasó‐Maristany and Montserrat Muñoz-Mateu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Benedetta Conte

37 papers receiving 563 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

2020 227 citations Olga Martínez‐Sáez, Núria Chic et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Benedetta Conte Italy	12	331	193	183	171	68	41	574
Mariana Brandão Belgium	16	468 1.4×	154 0.8×	200 1.1×	181 1.1×	44 0.6×	65	721
Christian Monnerat Switzerland	14	361 1.1×	187 1.0×	190 1.0×	66 0.4×	95 1.4×	34	645
César Sánchez Chile	14	425 1.3×	267 1.4×	180 1.0×	208 1.2×	121 1.8×	81	779
Sophie Barrett United Kingdom	9	295 0.9×	256 1.3×	54 0.3×	161 0.9×	54 0.8×	18	660
Connie G. Chiu Canada	14	304 0.9×	203 1.1×	103 0.6×	84 0.5×	43 0.6×	19	702
Αngeliki Andrikopoulou Greece	13	220 0.7×	158 0.8×	89 0.5×	78 0.5×	28 0.4×	41	438
Edoardo Crimini Italy	13	268 0.8×	129 0.7×	117 0.6×	146 0.9×	29 0.4×	39	474
Joseph Ayoub Canada	17	567 1.7×	485 2.5×	411 2.2×	71 0.4×	64 0.9×	26	1.1k
Claude El Kouri France	11	507 1.5×	429 2.2×	495 2.7×	178 1.0×	204 3.0×	20	903
Claudio Flores Peru	11	278 0.8×	85 0.4×	136 0.7×	85 0.5×	32 0.5×	41	493

Countries citing papers authored by Benedetta Conte

Since Specialization

Citations

This map shows the geographic impact of Benedetta Conte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benedetta Conte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benedetta Conte more than expected).

Fields of papers citing papers by Benedetta Conte

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benedetta Conte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benedetta Conte. The network helps show where Benedetta Conte may publish in the future.

Co-authorship network of co-authors of Benedetta Conte

This figure shows the co-authorship network connecting the top 25 collaborators of Benedetta Conte. A scholar is included among the top collaborators of Benedetta Conte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benedetta Conte. Benedetta Conte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schettini, Francesco, Tomás Pascual, Fara Brasó‐Maristany, et al.. (2023). 55P Clinicopathological and molecular changes induced by neoadjuvant therapy (NAT) in hormone receptor-positive (HR+)/HER2-low vs HER2 0 breast cancer (BC). ESMO Open. 8(1). 101279–101279. 1 indexed citations

Schettini, Francesco, Olga Martínez‐Sáez, Claudette Falato, et al.. (2023). Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis. ESMO Open. 8(3). 101214–101214. 8 indexed citations

Martínez‐Sáez, Olga, Fara Brasó‐Maristany, Mercedes Marín‐Aguilera, et al.. (2023). 8P First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer. ESMO Open. 8(1). 101232–101232.

Sharma, Priyanka, Shane R. Stecklein, Rachel Yoder, et al.. (2023). Abstract PD11-07: PD11-07 Association of TNBC-DX scores with outcomes in triple-negative breast cancer (TNBC) treated with neoadjuvant pembrolizumab and chemotherapy: a correlative analysis from NeoPACT and NeoSTOP trials. Cancer Research. 83(5_Supplement). PD11–7. 2 indexed citations

Morganti, Stefania, Fara Brasó‐Maristany, Tomás Pascual, et al.. (2023). 10P HER2 loss and PAM50 dynamics after neoadjuvant therapy (NAT) in HER2-positive (HER2+) early breast cancer (BC). ESMO Open. 8(1). 101234–101234. 1 indexed citations

Sirico, Marianna, Benedetta Conte, Milena Urbini, et al.. (2022). Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives. Critical Reviews in Oncology/Hematology. 181. 103900–103900. 14 indexed citations

Rodríguez, A., Olga Martínez‐Sáez, Fara Brasó‐Maristany, et al.. (2022). 263P Clinical outcomes in patients with germline pathogenic variants in homologous recombination repair (HRR) genes treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET). Annals of Oncology. 33. S657–S658. 2 indexed citations

Fregatti, Piero, Marco Gipponi, Marco Sparavigna, et al.. (2021). Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers. In Vivo. 35(1). 635–639. 2 indexed citations

Poggio, Francesca, Marco Tagliamento, Davide Soldato, et al.. (2020). Update on the Management of Breast Cancer during Pregnancy. Cancers. 12(12). 3616–3616. 38 indexed citations

10.

Cattrini, Carlo, et al.. (2020). Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer. Cancers. 12(8). 2325–2325. 53 indexed citations

11.

Tagliamento, Marco, Francesco Spagnolo, Francesca Poggio, et al.. (2020). Italian survey on managing immune checkpoint inhibitors in oncology during COVID‐19 outbreak. European Journal of Clinical Investigation. 50(9). e13315–e13315. 23 indexed citations

12.

Martínez‐Sáez, Olga, Tomás Pascual, Fara Brasó‐Maristany, et al.. (2020). 5P Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i). Annals of Oncology. 31. S17–S17.

13.

Molinelli, Chiara, Lucia Del Mastro, S. Giraudi, et al.. (2020). 226P Impact of BMI on outcome and cardiac safety in HER2-positive breast cancer patients treated with adjuvant trastuzumab: Results of a monocentric observational study. Annals of Oncology. 31. S331–S331. 1 indexed citations

14.

Schettini, Francesco, Núria Chic, Fara Brasó‐Maristany, et al.. (2020). 23P Clinical, pathological and gene expression features of HER2-low breast cancer. Annals of Oncology. 31. S24–S24. 1 indexed citations

15.

Lambertini, Matteo, Francesca Poggio, Marco Bruzzone, et al.. (2019). Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. International Journal of Cancer. 147(1). 160–169. 11 indexed citations

16.

Lambertini, Matteo, Marco Bruzzone, Francesca Poggio, et al.. (2019). The role of dose-dense (DD) adjuvant chemotherapy (CT) in HER2-positive (HER2+) early breast cancer (BC) patients (pts) before and after the introduction of trastuzumab (T): Exploratory analysis of the GIM2 trial. Annals of Oncology. 30. iii28–iii28. 1 indexed citations

17.

Blondeaux, Eva, Maurizio Cantore, Andrea Michelotti, et al.. (2019). Dose-dense adjuvant chemotherapy in early breast cancer: 15–year results of the phase III Mammella InterGruppo (MIG)-1 study. Annals of Oncology. 30. iii27–iii27. 1 indexed citations

18.

Poggio, Francesca, Marco Bruzzone, Marcello Ceppi, et al.. (2018). Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. ESMO Open. 3(4). e000361–e000361. 47 indexed citations

19.

Lambertini, Matteo, Valeria Fontana, Claudia Massarotti, et al.. (2018). Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study. The Breast. 41. 51–56. 26 indexed citations

20.

Giraudi, S., Andrea Michelotti, Andrea De Censi, et al.. (2016). Dose-dence adjuvant chemotherapy in early breast cancer: the results of 15 years of follow-up. Annals of Oncology. 27. iv61–iv61. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact